title: Effects of triple treatment with octreotide, galanin and serotonin on a human pancreas cancer cell line in xenografts.
abstract: Human pancreas cancer cells were implanted s.c. in nude mice. After 11 days, the mice were divided into two groups of 13. The first group received sterile saline solution and the second received triple therapy containing octreotide, galanin and serotonin, 40 microg/kg/day as a continuous i.p. infusion via an implanted osmotic pump for 14 days. Triple therapy prolonged the survival rate of the mice bearing human pancreatic carcinoma. Both the volume and weight of tumours in mice given triple therapy were less than in controls (not statistically significant). The proliferation index and the labelling index for epidermal growth factor (EGF) increased significantly in mice given triple therapy vis-a-vis controls. There was no statistically significant difference between control and treated tumours as regards, apoptotic index, necrosis, or number of tumour blood vessels. The increased survival rate was attributed to the reduced tumour load, since both weight and volume were reduced. It is most probable that octreotide was the responsible agent. Further investigation with single and double combinations of octreotide, galanin and serotonin are needed to identify the cause of increased cell proliferation in tumours subjected to these bioactive substances. Identifying the agent(s) inducing pancreatic cancer cell proliferation may be useful in combining a new treatment, as antagonists to these bioactive substances are available.
authors.affiliation: Division of Gastrotenterolgy, Molecular and Clinical Medicine, University Hospital, S-581 85 Linkoping, Sweden. magdy.el-salhy@imk.liu.se
authors.forename: M
authors.initials: M
authors.lastname: El-Salhy
authors.forename: V
authors.initials: V
authors.lastname: Tjomsland
authors.forename: E
authors.initials: E
authors.lastname: Theodorsson
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D001808:Blood Vessels / Q000187:drug effects / Q000473:pathology; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D004815:Epidermal Growth Factor / Q000378:metabolism; D066246:ErbB Receptors / Q000378:metabolism; D005260:Female; D019004:Galanin / Q000008:administration & dosage; D006801:Humans; D020287:In Situ Nick-End Labeling; D007263:Infusions, Parenteral; D051379:Mice; D008810:Mice, Inbred C57BL; D008819:Mice, Nude; D009374:Neoplasms, Experimental / Q000098:blood supply / Q000401:mortality / Q000517:prevention & control; D015282:Octreotide / Q000008:administration & dosage; D012701:Serotonin / Q000008:administration & dosage; D015996:Survival Rate; D016896:Treatment Outcome; D023041:Xenograft Model Antitumor Assays / Q000379:methods*
chemical_list: D012701:Serotonin; D004815:Epidermal Growth Factor; D019004:Galanin; D066246:ErbB Receptors; D015282:Octreotide